tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics initiated with an Outperform at Oppenheimer
The FlyEntrada Therapeutics initiated with an Outperform at Oppenheimer
9d ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
PremiumRatings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
25d ago
TRDA
Entrada Therapeutics highlights RNA pipeline progress and outlook
PremiumCompany Announcements
Entrada Therapeutics highlights RNA pipeline progress and outlook
29d ago
8K
TRDA
Entrada Therapeutics reports progress across development portfolio
PremiumThe Fly
Entrada Therapeutics reports progress across development portfolio
29d ago
TRDA
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
PremiumCompany Announcements
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
3M ago
TRDA
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target lowered to $13 from $17 at Roth Capital
3M ago
TRDA
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
Premium
Ratings
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
3M ago
TRDA
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
Premium
Ratings
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
3M ago
TRDA
Entrada Therapeutics files $400M mixed securities shelf
PremiumThe Fly
Entrada Therapeutics files $400M mixed securities shelf
3M ago
TRDA
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
PremiumThe Fly
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
3M ago
TRDA
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
PremiumRatings
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
3M ago
TRDA
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
3M ago
EXOD
NRIX
Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
PremiumThe FlyEntrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
5M ago
TRDA
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
6M ago
TRDA
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
Premium
Ratings
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
6M ago
TRDA
Entrada Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Entrada Therapeutics Reports Q2 2025 Financial Results
6M ago
TRDA
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
PremiumRatings
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
6M ago
TRDA
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
PremiumThe Fly
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
6M ago
TRDA
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
PremiumCompany Announcements
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
8M ago
8K
TRDA
Entrada Therapeutics Appoints New Board Member
PremiumCompany AnnouncementsEntrada Therapeutics Appoints New Board Member
8M ago
8K
TRDA
Entrada Therapeutics appoints Radhakrishnan to board of directors
Premium
The Fly
Entrada Therapeutics appoints Radhakrishnan to board of directors
8M ago
TRDA
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
Premium
Ratings
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
8M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >